| Catalog No. | AY257014 |
|---|
| Applications | ELISA |
|---|
| Host species | Rabbit |
|---|
| Isotype | IgG |
|---|
| Clonality |
Polyclonal |
| Immunogen |
Obinutuzumab |
| Target |
Rabbit polyclonal to Gazyva. |
| Specificity |
The product is specific for Obinutuzumab. This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays. |
| Endotoxin level |
Please contact with the lab for this information. |
| Purification |
Purified by antigen affinity column. |
| Accession |
CAS: 949142-50-1 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Product Usage Information |
| Application |
Dilution |
| ELISA |
1:5000-1:20000 |
| IHC |
1:50-1:500 |
| WB |
1:500-1:2000 |
|
|---|
| Stability and Storage |
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
| Background | Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
|
|---|
| Note |
For research use only. |
中文
English
